NATIONAL INSTITUTES OF HEALTH

Mission Bio announces 20+ presentations at ASH 2024 showcasing Tapestri Platform's impact on hematology, including new datasets on Multiple Myeloma, AML, and CAR-T therapy development.

Experts convened at the ImmunOptimize workshop to address the unmet needs of immunocompromised patients, advocating for a clinical trials network to improve evidence-based treatment and prevention of infectious diseases in this population.

Eisai and Biogen announce COFEPRIS approval of LEQEMBI® (lecanemab) for early Alzheimer’s disease, targeting soluble and insoluble Aβ aggregates. LEQEMBI is the first treatment shown to reduce disease progression and cognitive decline, already approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, the UAE, and Great Britain. The approval is based on the Phase 3 Clarity AD study, which met primary and secondary endpoints with significant results.

NIH study found 48.6% of pregnant people with abnormal prenatal cfDNA test results had undetected cancers, including colorectal, breast, lung, and pancreatic cancers. Whole body MRI was most effective in detecting these cancers. The study highlights the need for further research to validate cfDNA sequencing patterns indicating cancer in asymptomatic pregnant individuals.

High-profile dementia researchers, including Eliezer Masliah, have been accused of fraud, influencing neurological research and drug trials. Dr. Matthew Schrag, a neurologist, investigates such misconduct, emphasizing the need for research integrity and high-quality data. Schrag highlights the challenges in spotting fraud and the ethical concerns of running trials based on potentially fraudulent data, advocating for a broader approach to Alzheimer's research beyond the amyloid hypothesis.

Eisai announced COFEPRIS approval of Leqembi (lecanemab) for early Alzheimer's disease in Mexico. Leqembi, developed by BioArctic and Eisai, targets amyloid-beta aggregates, reducing disease progression. It's also approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, and Great Britain.